Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

BD, JDRF partner to accelerate development of glucose-sensing technology for T1D

JDRF and BD today announced an extension of their existing collaboration focused on Type 1 diabetes (T1D) to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information.

From BD (Becton, Dickinson and Company) 8 Jun 2012

Researchers identify brain receptor that appears to play a central role in regulating appetite

Researchers at Columbia University Medical Center (CUMC) have identified a brain receptor that appears to play a central role in regulating appetite. The findings, published today in the online edition of Cell, could lead to new drugs for preventing or treating obesity.

8 Jun 2012

Study reviews role of gut microbes in nutrient absorption and energy regulation

Microorganisms in the human gastrointestinal tract form an intricate, living fabric made up of some 500 to 1000 distinct bacterial species, (in addition to other microbes). Recently, researchers have begun to untangle the subtle role these diverse life forms play in maintaining health and regulating weight.

7 Jun 2012

GLP-1 receptor agonist boosts glycemic control in Asian patients

Adding once-daily lixisenatide to basal insulin treatment is effective at improving glycemic control in Asian patients with Type 2 diabetes, show study findings.

6 Jun 2012

New tool helps researchers to better understand Type 2 human diabetes

With Type 2 human diabetes climbing at alarming rates in the United States, researchers are seeking treatments for the disease, which has been linked to obesity and poor diet. Now biologists at Southern Methodist University, Dallas, report they have developed a new tool that will help researchers better understand this deadly disease.

6 Jun 2012

PhaseBio raises $48.4M in Series B financing

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has raised a total of $48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs.

6 Jun 2012

UCSD researchers receive $4M NIMH grant to study accelerated biological aging in schizophrenia

Researchers at the Stein Institute for Research on Aging at the University of California, San Diego have received a $4 million grant from the National Institute of Mental Health (NIMH), part of the National Institutes of Health, to study accelerated biological aging in schizophrenia.

6 Jun 2012

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.

5 Jun 2012

GPR21 inhibitors may hold promise for diabetes

In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into other tissues. Obesity is a major factor that contributes to insulin resistance, which can eventually lead to type 2 diabetes. Previous studies have shown that proinflammatory molecules found in fat tissue decreases sensitivity of tissues to insulin.

2 Jun 2012

Cera announces new citrus ready-to-drink oral rehydration solution

Cera Products is proud to announce its new CeraLyte-70 Citrus Ready to Drink in a 500 ml environmentally green container with a re-closeable top and a long shelf-life. No mixing is needed, saving health care staff time when fast patient hydration is needed.

2 Jun 2012

First study to correlate dietary fiber intake with inflammatory markers in adolescents

Adolescents who don't eat enough fiber tend to have bigger bellies and higher levels of inflammatory factors in their blood, both major risk factors for cardiovascular disease and diabetes, researchers report.

2 Jun 2012

Janssen submits canagliflozin NDA with FDA for treatment of type 2 diabetes

Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.

1 Jun 2012

Researchers investigate how iPFK2 enzyme may benefit some obese people

Why is it that some obese people are healthier than others? This was one of the main questions Dr. Chaodong Wu of the College of Agriculture and Life Sciences - Texas A&M University System - and a group of researchers tried to answer in a recent study.

1 Jun 2012

Risk of gout flare-ups greatly increased by purine rich foods

Foods rich in purines, particularly those found in meat and seafood, quintuple the immediate risk of a gout flare-up, finds research published online in the Annals of the Rheumatic Diseases.

31 May 2012

Insulin use linked to lung cancer risk in diabetes

Postmenopausal women with treated diabetes may be at an increased risk for lung cancer, particularly if they are on insulin, say researchers.

30 May 2012

Childhood obesity risk linked to delivery method

Delivery by cesarean section may double the risk for childhood obesity compared with vaginal delivery, show US study findings.

30 May 2012

Intensive wellness program addresses multiple aspects of diabetes care

An integrated wellness team approach to diabetes care is helping patients lower their prescription costs and improve their condition, according to research presented today at the American Association of Clinical Endocrinologists' (AACE) 21st Annual Scientific & Clinical Congress in Philadelphia.

28 May 2012

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

28 May 2012